Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

48 results about "Pipequaline" patented technology

Pipequaline (INN) (developmental code name PK-8165) is an anxiolytic drug that was never marketed. It possesses a novel chemical structure that is not closely related to other drugs of this type. The drug has a similar pharmacological profile to the benzodiazepine family of drugs, but with mainly anxiolytic properties and very little sedative, amnestic or anticonvulsant effects, and so is classified as a nonbenzodiazepine anxiolytic.

Diagnostic marker for metabolic syndrome and preclinical stage thereof and application of diagnostic marker

PendingCN119246661AConducive to clinical promotion and applicationHelps with health managementMass spectrometric analysisMaterial analysis by electric/magnetic meansPipequalinePipecolic acid
The invention provides a diagnostic marker for metabolic syndrome and preclinical stage thereof, and the diagnostic marker or a plasma small molecule metabolism biomarker consists of the following substances: pyrimidine, (S)-beta-aminoisobutyric acid, 3-hydroxybutyric acid, L-serine, guanidine acetic acid, 3-hydroxyisovaleric acid, L-homoserine, L-cysteine, piperidine acid, hypotaurine and creatinine. The beverage is prepared from phenylacetic acid, erythritol, picolinic acid, taurine, pyroglutamic acid, lemonic acid, malic acid, tyramine, isonicotinic acid, o-phosphoethanolamine, L-glutamine, salicylic acid and D-glucose. The invention also provides a kit for detecting the plasma small molecule metabolism biomarker composition, the spectrum peak intensity of the obtained plasma small molecule metabolism biomarker is detected, the risk score of whether each subject is MetS or pre-MetS is calculated, and then whether the subject is MetS or pre-MetS is predicted. According to the invention, efficient and rapid diagnosis of the metabolic syndrome and the preclinical stage thereof is realized.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

A quantitative method for determining a mental state based on DRD1 and / or DRD5, and its application

A method for treating a mental disorder in a subject, comprising the step of normalizing the expression of both DRD1 and DRD5 belonging to the DRD1-like family of the subject to a preset standard level. The DRD1 / 5 level and expression can be increased or decreased bidirectionally by targeting the upstream promoter sequence of DRD1 / 5. The promoter activity of DRD1 / 5 can be attenuated by using antipsychotic drugs that directly target the DRD1 / 5 promoter. The antipsychotic drugs used are typical and / or atypical antipsychotic drugs such as haloperidol, risperidone, clozapine, and cariprazine. This treatment is also useful for subjects in whom the constitutive expression of the DRD1 / 5 gene is impaired. This method can be used to treat schizophrenia, autism, depression, mania, and bipolar disorder by normalizing the DRD1 / 5 expression level. The promoter gene sequencing of DRD1 and / or DRD5 can also be used for quantitative mental health screening by comparing with a standard sequence database.
Owner:シシャンドン

Centrally-active ghrelin agonist and medical uses thereof

The new compound 3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea monohydrochloride salt has a high capability to permeate through the blood-brain barrier and to display, at central nervous system level, a consistent ghrelin agonist activity; the compound is effective in the treatment and / or prevention of a medical condition mediated by the ghrelin receptor in the central nervous system. In particular, in experimental tests, the compound has shown high efficacy in the treatment of neurotoxic damage, with a useful combined pattern of neuroprotective effects both at central and peripheral level. The compound is further useful in the treatment of conditions which require a reduction of the heart rate. The compound is pharmacologically active at low to moderate doses, thus showing a favourable therapeutic index.
Owner:HELSINN HEALTHCARE SA

Application of thiophene pyrimidone derivative in preparation of medicine for treating Alzheimer disease

The invention discloses application of a thiophene pyrimidone derivative in preparation of a medicine for treating Alzheimer's disease, and belongs to the technical field of medicines, and the thiophene pyrimidone derivative is 2-[(4-methylpiperidine-1-yl) methyl]-3-(tetrahydrofuran-2-yl methyl)-5-(thiophene-2-yl) thieno [2, 3-d] pyrimidine-4-ketone. According to the application of the thiophene pyrimidinone derivative in preparation of the medicine for treating the Alzheimer's disease, 2-[(4-methylpiperidine-1-yl) methyl]-3-(tetrahydrofuran-2-yl methyl)-5-(thiophen-2-yl) thieno [2, 3-d] pyrimidin-4-one has an efficient inhibition effect on BChE, can remarkably improve the cognitive function defect of an AD model, and can be used for preparing the medicine for treating the Alzheimer's disease. A novel efficient BChE targeting candidate inhibitor is provided for the field of AD treatment.
Owner:LUDONG UNIVERSITY

Combination of a menin inhibitor with a pyrazolopiperidine GLP-1 receptor agonist for treating diabetes and obesity

PCT designated stageWO2026055512A1Organic active ingredientsMetabolism disorderDiabetes mellitusPipequaline
Disclosed herein are combinations comprising an GLP-1R agonist and an inhibitor of menin. Also described are combinations of specific GLP-1R agonists and irreversible inhibitors or reversible inhibitors of menin. Also described are methods of using the combinations for the treatment of diabetes, obesity and overweight condition.
Owner:BIOMEA FUSION INC

Crystal form of substituted 1-(3, 3-difluoropiperidine-4-yl)-imidazo [4, 5-C] quinoline-2-ketone derivative, crystal form of salt of substituted 1-(3, 3-difluoropiperidine-4-yl)-imidazo [4, 5-C] quinoline-2-ketone derivative, preparation method and application

PendingCN118984706ALow efflux rateDecreased efflux rateOrganic active ingredientsOrganic chemistry methodsDiseasePipequaline
The invention provides a free alkali crystal form and a salt crystal form of a substituted 1-(3, 3-difluoropiperidine-4-yl)-imidazo [4, 5-c] quinoline-2-ketone derivative (shown in a formula (I)) as well as a preparation method and application of the free alkali crystal form and the salt crystal form, and particularly relates to the free alkali crystal form and the fumarate crystal form of the 1-(3, 3-difluoropiperidine-4-yl)-imidazo [4, 5-c] quinoline-2-ketone derivative shown in the formula (I). The free alkali crystal form and the salt crystal form provided by the invention are good in stability, can be used for treating diseases such as cancers, cancers accompanied by central nervous system metastasis, meningeal metastasis, primary brain cancer or glioma (especially combined treatment with a DNA double-strand breakage inducer), have good bioavailability and half-life period, and can be used for preparing a medicine for treating the diseases such as the cancers, the cancers accompanied by central nervous system metastasis, meningeal metastasis, primary brain cancer or glioma and the like. The method is of great significance to further research on the curative effect of the solid preparation. # imgabs0 #
Owner:钟卫

Drug formulations of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4- phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3H)-one

PCT designated stage expiredWO2024137604A8Organic active ingredientsAntipyreticPipequalineTyrosine
This disclosure relates to the field of therapeutic Bruton's tyrosine kinase (BTK) inhibitors. Pharmaceutical formulations of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one are described.
Owner:PRINCIPIA BIOPHARMA INC

Salt and crystal form of polycyclic anaplastic lymphoma kinase inhibitor

The invention relates to a salt and a crystal form of a polycyclic anaplastic lymphoma kinase inhibitor, a preparation method of the salt and the crystal form, a pharmaceutical composition containing the salt and the crystal form, and application of the salt and the crystal form or the pharmaceutical composition. Specifically, the invention relates to a salt and a crystal form of a compound 5-chloro-N4-(2-(isopropyl sulfonyl) phenyl)-N2-(7-methyl-8-(piperidine-4-yl)-2, 3-dihydrobenzo [b] [1, 4] dioxin-5-yl) pyrimidine-2, 4-diamine used as an anaplastic lymphoma kinase inhibitor, a preparation method of the salt and the crystal form, a pharmaceutical composition containing the salt and the crystal form, and a preparation method of the pharmaceutical composition. The invention also discloses application of the salt and the crystal form or the pharmaceutical composition in drugs for preventing and / or treating anaplastic lymphoma kinase mediated cancers or non-cancerous related diseases.
Owner:XUANZHU BIOPHARMACEUTICAL CO LTD

Pipemidic acid-thiadiazole hybrid system with antibacterial and anti-inflammatory effects

ActiveDE202025106988U1Organic chemistryPipemidic acidPipequaline
A system comprising pipemidic acid-1,3,4-thiadiazole hybrid derivatives with a thiadiazole group at position C-6 of the pipemidic acid skeleton, synthesized and structurally determined by IR-, 1 H-NMR-, 13 Confirmed by C-NMR and mass spectrometry.
Owner:MAHARISHI MARKANDESHWAR (DEEMED TO BE UNIVERSITY) AMBALA

2'-6'-pipecoloxylidide as a sensory-selective anesthetic

A method of inducing local anesthesia in a subject includes administering to the subject in need thereof 2',6'-pipecoloxylidide (PPX) or a pharmaceutically acceptable salt thereof in an amount effective to induce local anesthesia in the subject. An active molecule that is metabolized to PPX in the subject is not administered to the subject with the PPX.
Owner:CHILDRENS MEDICAL CENT CORP

Benzopiperidine biquaternary ammonium salt compound and application thereof in medicine

The invention relates to a benzopiperidine biquaternary ammonium salt compound and application thereof in medicine, in particular to a compound shown in a general formula (I) or a stereoisomer, a racemate, a tautomer, pharmaceutically acceptable salt, an intermediate and a pharmaceutical composition of the compound, and application of the compound in preparation of neuromuscular blocking drugs.
Owner:HAISCO PHARMACEUTICAL GROUP CO LTD

Quantitative determination method for mental state based on DRD1 and / or DRD5 and application of quantitative determination method

A method of treating a psychiatric disorder in a subject comprises the step of normalizing the expression of DRD1 and DRD5 belonging to DRD1 class receptors in the subject to a preset standard level. By targeting an upstream promoter sequence of DRD1 / 5, the level and expression of DRD1 / 5 can be bidirectionally increased or decreased. The use of antipsychotic agents that directly target the DRD1 / 5 promoter can attenuate the DRD1 / 5 promoter activity. The antipsychotic agents used are typical and / or atypical antipsychotic agents, such as haloperidol, risperidone, clozapine and cariprazine. The treatment is also useful for subjects in which constitutive expression of the DRD1 / 5 gene is impaired. The methods can treat schizophrenia, autism, depression, mania, and bipolar affective disorders by normalizing DRD1 / 5 expression levels. Promoter gene sequencing of DRD1 and / or DRD5 can also be used for quantitative mental health screening by comparison to a standard sequence database.
Owner:施显东

Methods of treating systemic lupus erythematosus using BTK inhibitors

Provided herein are methods of treating systemic lupus erythematosus including lupus nephritis, in particularly active proliferative lupus nephritis in a subject with (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo-[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof.
Owner:BEONE MEDICINES I GMBH

Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use

Provided herein are methods of using (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, in combination with a second active agent for treating, preventing or managing hematological malignancies. The second active agent is one or more of an HDAC inhibitor, a BCL2 inhibitor, a BTK inhibitor, an mTOR inhibitor, a PI3K inhibitor, a PKCβ inhibitor, a SYK inhibitor, a JAK2 inhibitor, an Aurora kinase inhibitor, an EZH2 inhibitor, a BET inhibitor, a hypomethylating agent, a DOT1L inhibitor, a HAT inhibitor, a WDR5 inhibitor, a DNMT1 inhibitor, an LSD-1 inhibitor, a G9A inhibitor, a PRMT5 inhibitor, a BRD inhibitor, a SUV420H1 / H2 inhibitor, a CARM1 inhibitor, a PLK1 inhibitor, an NEK2 inhibitor, an MEK inhibitor, a PHF19 inhibitor, a PIM inhibitor, an IGF-1R inhibitor, an XPO1 inhibitor, a BIRC5 inhibitor, or a chemotherapy.
Owner:CELGENE CORP

Centrally-Active Ghrelin Agonist and Medical Uses Thereof

The new compound 3-(1-(2,3-dichloro-4-methoxyphenyl) ethyl)-1-methyl-l-(l,3,3-trimethylpiperidin-4-yl)urea monohydrochloride salt has a high capability to permeate through the blood-brain barrier and to display, at central nervous system level, a consistent ghrelin agonist activity; the compound is effective in the treatment and / or prevention of a medical condition mediated by the ghrelin receptor in the central nervous system. In particular, in experimental tests, the compound has shown high efficacy in the treatment of neurotoxic damage, with a useful combined pattern of neuroprotective effects both at central and peripheral level. The compound is further useful in the treatment of conditions which require a reduction of the heart rate. The compound is pharmacologically active at low to moderate doses, thus showing a favourable therapeutic index.
Owner:HELSINN HEALTHCARE SA

Polymorphs of Bruton's tyrosine kinase inhibitors and their preparation methods and applications

The present invention provides polymorphs of Bruton's tyrosine kinase inhibitors, their preparation methods, and uses. Specifically, two crystalline forms of (R)-6-((1-acryloylpiperidin-3-yl)amino)-7-fluoro-4-((2-fluoro-4-morpholinophenyl)amino)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one, their preparation methods, and uses are provided. The two crystalline forms provided by the present invention have good stability, are not hygroscopic, have improved solubility and pharmacokinetic characteristics, and the preparation method is stable and capable of large-scale production.
Owner:SHANGHAI HAIYAN PHARMA TECH +1

Treatment of CNS conditions

Aspects of the present invention relate to a method of treating an epileptic encephalopathy in a mammal in need thereof, comprising administering a composition comprising an effective amount of (1-benzyl-1-hydroxypiperidin-1-yl) (2,4′-bipyridin-3-yl)methanone or a pharmaceutically acceptable salt thereof to the mammal.
Owner:TAKEDA PHARMA CO LTD

A 6-(6-methyl-1h-pyrrolo[2,3-b]pyridin-3-yl)quinazoline-4-amine derivative, and a preparation method and application thereof

PendingCN122277556AGuaranteed inhibitory activityHighly balanced activityPipequalineSide chain
This invention relates to the field of pharmaceutical technology, specifically to a 6-(6-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)quinazoline-4-amine derivative, its preparation method, and its applications. This invention utilizes a "conformation-locking" and "drug-likeness optimization" strategy to optimize the 4-position side chain of quinazoline into conformationally defined structures such as dihydroindanol and fluoropiperidine, thereby reducing P-gp recognition through conformational rigidity. Simultaneously, the introduction of groups such as cyclopropylformyl groups reduces off-target toxicity, thus broadening the therapeutic window. The 6-(1H-pyrrolo[2,3-b]pyridin-3-yl)quinazoline-4-amine derivative provided by this invention simultaneously achieves potent DYRK1A inhibition, high kinase selectivity, low microglial cytotoxicity, significant anti-neuroinflammatory effects, good blood-brain barrier permeability, and oral bioavailability. Furthermore, it is a novel small-molecule inhibitor that can be validated for cognitive improvement in AD animal models, possessing significant clinical value and urgent application needs.
Owner:GENERAL HOSPITAL OF THE NORTHERN WAR ZONE OF THE CHINESE PEOPLES LIBERATION ARMY

Prophylactic or therapeutic for GM1 gangliosidosis, and composition for preventing or treating GM1 gangliosidosis

ActiveJP2025001027ANervous disorderMetabolism disorderAcacetinPipequaline
To provide a novel prophylactic or therapeutic for GM1 gangliosidosis, and a novel composition for preventing or treating GM1 gangliosidosis.SOLUTION: Provided is a prophylactic or therapeutic for GM1 gangliosidosis, comprising, as an active ingredient, at least one selected from the group consisting of amodiaquine, acacetin, sulfamerazine, ungerine, amiodarone, sertindole, delcorine, perphenazine, althiazide, diethylstilbestrol, thiethylperazine, harmol, skimmianine, succinylsulfathiazole, phillalbine, canavanine, harmaline, trihexyphenidyl, fluoxetine, lovastatin, haloperidol, prenylamine lactate, bromperidol, convolvamine, and miglustat, and pharmaceutically acceptable salts thereof, or solvates thereof.SELECTED DRAWING: Figure 5
Owner:NAT UNIV CORP KUMAMOTO UNIV

N-(3 / 4-((6-substituted pyrimidine-4-yl) amino) phenyl) amide derivative and application thereof

The invention discloses an N-(3 / 4-((6-substituted pyrimidine-4-yl) amino) phenyl) amide derivative and application thereof, and belongs to the field of medical chemistry. The structural formula of the compound is as follows: R1 is 4-methyl-1H-imidazole-1-group, 3-methyl-1H-pyrazole-1-group or 4-methyl-1H-pyrazole-1-group, R2 is 4-methyl-1H-imidazole-1-group, and R3 is 3-methyl-1H-pyrazole-1-group; r2 is a linear alkyl group, a cycloalkyl group, a 1-methylpiperidine-4-group, a morpholinyl ethyl group, a substituted or unsubstituted phenyl group, a substituted or unsubstituted styryl group, a substituted or unsubstituted phenethyl group, a phenylpropyl group, a phenylbutenyl group, a 6-bromo-pyridine-2-group, a (benzo [d] [1, 3] dioxol-5-group) vinyl group or a (thiophene-2-group) methyl group. The invention relates to a novel Nur77 targeted giant vesicle type death inducer which is suitable for single-drug treatment of lung cancer or is combined with other targeted / immune / chemotherapeutic drugs to improve the curative effect and reduce the drug resistance risk. And the Nur77 can be expanded to breast cancer, liver cancer and other Nur77 related tumors.
Owner:XIAMEN UNIV

Detection method of R-3-aminopiperidine dihydrochloride

InactiveCN119715873AComponent separationDipeptidyl peptidasePipequaline
The invention belongs to the technical field of drug analysis and detection, and particularly relates to a detection method of R-3-aminopiperidine dihydrochloride. According to the method, 0.07-0.2 vol% formic acid aqueous solution and acetonitrile are taken as mobile phases, gradient elution is carried out according to a specific ratio, and qualitative and quantitative analysis can be carried out on R-3-aminopiperidine dihydrochloride by combining mass spectrometric detection; according to the present invention, the method has characteristics of rapid detection and rapid analysis, the target peak pattern is good, the peak can appear after about 0.6-0.9 min, the whole detection time is within 5 min, rapid detection and analysis can be achieved, methodological investigation results prove that the method has advantages of high precision, good repeatability, high accuracy and high sensitivity, and the measured R-3-aminopiperidine dihydrochloride still presents the good linear relationship in the extremely low concentration range of 1.018-203.6 ng / mL, the method is favorable for monitoring the R-3-aminopiperidine dihydrochloride in the production of the ridipeptidyl peptidase-4 inhibitor.
Owner:ZHUZHOU QIANJIN PHARMA +1

κ-opioid receptor agonists and their uses

The present invention belongs to the field of biopharmaceuticals and provides a κ-opioid receptor agonist having the following formula, its stereoisomers, and pharmaceutically acceptable salts thereof. The κ-opioid receptor agonist has high selectivity for the κ-opioid receptor, its activity is 3 to 15 times that of diferikephalin, and has high pharmacological activity, and can be used for the treatment, prevention and / or remission of pruritus, and / or analgesia. D-Phe-AA1-AA2-D-Lys-4-aminopiperidine-4-carboxamide-AA3-AA4-AA5 [Formula I].
Owner:CHENGDU AODA BIOTECHNOLOGY CO LTD

Application of 1-((4-cyclohexylphenyl) sulfonyl)-N-(4-fluorobenzyl)-4-methylpiperidine-4-formamide in preparation of medicine for treating nervous system diseases

The invention belongs to the technical field of drug development, and particularly relates to application of 1-((4-cyclohexylphenyl) sulfonyl)-N-(4-fluorobenzyl)-4-methylpiperidine-4-formamide in preparation of drugs for treating nervous system diseases. The invention aims to provide a medicine which has small toxic and side effects and can target SLC11A2 to treat or improve nerve cell injury. According to the technical scheme, the invention relates to application of 1-((4-cyclohexylphenyl) sulfonyl)-N-(4-fluorobenzyl)-4-methylpiperidine-4-formamide in preparation of a medicine for treating nervous system diseases. It is proved that the compound 1-((4-cyclohexylphenyl) sulfonyl)-N-(4-fluorobenzyl)-4-methylpiperidine-4-formamide is small in toxic and side effect, and nerve cell damage can be protected or improved by targeting SLC11A2; and a new choice is provided for treating or improving nerve cell injury.
Owner:广州市老人院(加挂广州市第二老人院和广州市老年医院牌子)

Methods for treating primary membranous nephropathy

Provided herein is a method of treating primary membranous nephropathy in a patient in need thereof, comprising administering to the patient a BTK inhibitor, for example, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, or a pharmaceutically acceptable salt, tautomer, stereoisomer, enantiomer, isotope, solvate, or prodrug thereof.
Owner:BEIGENE SWITZERLAND GMBH